Kalbe Farma Stock - sector comparison after quiet news week
19.06.2026 - 19:30:47 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 19:29 CET. Details in the imprint.
Kalbe Farma (ID1000096605) remains without a new investor-relations update or major wire report this week. With no fresh hook from official disclosures or leading news agencies, attention on Friday turns to how the Indonesian pharmaceutical group is positioned in its sector and peer landscape.
Background and price data on Kalbe Farma stock
Key figures, regulatory filings and further company news on Kalbe Farma can be found in the dedicated topic area and on the group's investor-relations pages.
What official sources show
Kalbe Farma describes itself in its latest company profile as one of Indonesia's largest publicly listed healthcare groups, with activities spanning prescription drugs, over-the-counter medicines, nutritionals and distribution services. The business overview is outlined on the company's own investor-relations portal. The IR pages detail the four main business segments and recent financial highlights.
The stock is quoted on the Indonesia Stock Exchange under the ticker KLBF, with trading in Indonesian rupiah. According to public exchange data, Kalbe Farma is classified within the healthcare and pharmaceutical segment on the Jakarta bourse, alongside other Indonesian drugmakers and healthcare service providers.
How Kalbe stacks up in sector terms
On a sector basis, Kalbe Farma competes with Indonesian peers such as Kimia Farma and state-linked healthcare firms, while also facing competition from multinational groups active in Southeast Asia. Publicly available market commentary often highlights Kalbe's relatively diversified portfolio compared with smaller single-line producers.
Regionally, the broader Asian pharmaceutical and healthcare space has seen mixed performance in recent sessions, with some listed drugmakers in India, South Korea and Japan posting more volatile moves than the comparatively stable Indonesian majors. Against this backdrop, Kalbe Farma shares have shown a more muted pattern this week than some higher-beta regional peers, according to regional quote overviews.
The business behind the stock
Kalbe Farma generates revenue from a combination of prescription pharmaceuticals, consumer health products, nutritional products and a large distribution network across Indonesia. The group emphasizes chronic disease treatments, vitamins and functional foods as structural growth drivers in its corporate materials.
Where the stock trades today
Kalbe Farma shares (ID1000096605) trade on the Indonesia Stock Exchange in Indonesian rupiah; the latest available public quote data show the stock changing hands on the Jakarta market, with exact real-time levels depending on intraday trading at the time of access.
Kalbe Farma at a glance
- Company: PT Kalbe Farma Tbk
- ISIN: ID1000096605
- WKN: not available
- Ticker: KLBF
- Venue: Indonesia Stock Exchange (IDX)
- Price (as of latest available Jakarta trading data): not disclosed here due to intraday fluctuations
- Market cap: publicly available on IDX and major financial data platforms
- Sector / Industry: Healthcare - Pharmaceuticals
- Index membership: included in Indonesian equity indices that track major healthcare and blue-chip stocks, according to IDX classifications
- Next earnings date: next quarterly reporting date not officially scheduled on the IR calendar at the time of writing
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
